Skip to content

Released Nov 13, 2012, before the open

10-Q filed Nov 13, 2012, 44 days after period end · 0001193125-12-465472

Q3 2012 · 10-Q
Revenue$2.17Mno prior Q3 2011 on file−36.0% vs Q2 2012
Net Income-$18.03MN/M vs Q3 2011N/M vs Q2 2012
EPS Diluted-$0.09N/M vs Q3 2011N/M vs Q2 2012
Gross Profit$1,454,000—
Operating Income-$5,528,000—
Operating Cash Flowderived-$4,165,000N/M
Margins · derived
Gross margin67.1%
Operating margin-255.2%
Net margin-832.2%

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ3 2012Q3 2011Q3 2010
Revenue$2.17M——
Net Income-$18.03M-$5.48M-$4.14M
EPS Diluted-$0.09-$0.14-$0.23

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR